Safe Harbor Statement

6/7/2004


Click here to start


Table of Contents

PPT Slide

Safe Harbor Statement

Building a Biopharmaceutical Company

Executing to Plan

Significant Presence at 2004 ADA Meeting

Continued Progress on Exenatide

Improving Delivery Exenatide LAR

Robust Product Pipeline

2004 Corporate Goals

Exenatide Clinical Leadership

PPT Slide

Type 2 Diabetes Needs New Treatments

Type 2 Diabetes: The Underlying Defects

Beta-cell Defect

Exenatide Targets Beta Cells

Exenatide Restored First Phase Insulin

Exenatide in Clinical Practice

PPT Slide

Exenatide Pivotal Studies

Exenatide Pivotal Studies (AMIGOs)

Consistent Demographics Across AMIGOs

Exenatide Lowered A1C

Exenatide Lowered Fasting Plasma Glucose

Exenatide Improved Postprandial Glucose

Exenatide Lowered Body Weight

Combined AMIGOs: Adverse Events

Combined AMIGOs: Adverse Events

AMIGOs: Summary

Antibody Formation

Exenatide Showed Durable Effect on A1C

Exenatide Showed Durable Effect on Weight

Exenatide: Potential Type 2 Diabetes Therapy

PPT Slide

Author: Amylin Employee